Pilot Study of the Effect of Romiplostim on Child Health-Related Quality of Life (HRQoL) and Parental Burden in Immune Thrombocytopenia (ITP)

Authors

Robert J. Klaassen MD, Children's Hospital of Eastern Ontario
Susan D. Mathias MPH, Health Outcomes Solutions
Georg Buchanan MD, University of Texas Southwestern Medical Center at Dallas
James Bussel MD, New York Presbyterian Hospital
Robert Deuson PhD, Amgen Inc.
Nancy L. Young PhD, Laurentian University of Sudbury
Anderson B. Collier MD, Lehigh Valley Health NetworkFollow
Lisa Bomgaars MD, Texas Children's Cancer Center
Victor Blanchette MD, University of Toronto

Publication/Presentation Date

3-2012

Volume

58

Issue

3

First Page

395

Last Page

398

ISSN

1545-5009

Published In/Presented At

Klaassen RJ; Mathias SD; Buchanan G; Bussel J; Deuson R; Young NL; Collier A; Bomgaars L; Blanchette, V. (2012). Pilot study of the effect of romiplostim on child health-related quality of life (HRQoL) and parental burden in immune thrombocytopenia (ITP). Pediatric Blood & Cancer, 58(3), 395-398. doi:10.1002/pbc.23312

Disciplines

Medicine and Health Sciences | Pediatrics

PubMedID

21910213

LVHN link

http://search.ebscohost.com/login.aspx?direct=true&db=mnh&AN=21910213&site=ehost-live&scope=site

Department(s)

Department of Pediatrics

Document Type

Article